Loading…

LupinLUPIN.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Other

Mumbai generic drugmaker known for respiratory, cardiovascular and anti-TB medicines, sold mainly in the US and India.

≈ A smaller, generics-focused ViatrisMomentum weak 30
Mkt cap
$9.67B
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$14.8M
20-day average traded
Fwd P/E
21.0×
forward earnings
ROIC−WACC
+11.6 pp
WACC 12.4%
Hurdle
-4 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹1,972
1D+1.1%
1W-2.5%
1M+1.7%
3M-11.7%
6M-13.8%
YTD-6.5%
1Y-3.0%
ATR %2.1%
Beta0.46
52w lowhigh22.0% off high

What Lupin does

Mumbai generic drugmaker known for respiratory, cardiovascular and anti-TB medicines, sold mainly in the US and India.

The US, where it sells generics to pharmacy chains and wholesalers, is the largest market, followed by India, where branded prescription drugs, especially chronic-disease medicines, are sold through doctors. Founded in 1968 by Desh Bandhu Gupta, whose family still leads and controls it.

In one line: A smaller, generics-focused Viatris.

Products and services

  • US generics
  • India branded formulations
  • Complex generics (inhalation, injectables)
  • Anti-TB / emerging markets
  • APIs

Customers

  • US retail/distributor pharmacy channel
  • Indian doctors and hospitals
  • Global TB treatment programmes

Where it sits in the supply chain

  • Pharmaceuticals
  • Generic & branded generics
  • Respiratory / cardiovascular

What could go right

  • US complex-generic pipeline
  • India chronic-therapy growth

What could go wrong

  • US pricing pressure
  • Plant compliance/FDA risk

Moat: narrow (regulatory licence, brand, process know-how). Strong India brand plus complex-generic (inhaler, injectable) approvals in the US.

Headquarters: Mumbai, India · Founded: 1968 · Employees: 28,137

Named competitors

Lupin at a glance

Size Lupin (LUPIN.NS) is an India Health Care company (Pharmaceuticals: Other) with a market value of $9.67B, the 130th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,972 on 18 Nov 2026.

Performance Over six months the shares fell 13.8%, against +0.5% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 12 in its peer set.

Growth Revenue grew 24.2% over the last twelve months (peer median +10.1%); the operating margin is 23.8% (peer median 13.9%).

Valuation It trades at 21.0× forward earnings against a peer median of 20.1× (5th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.6 points above its cost of capital (12.4% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 101LUPIN.NS 86
Six months, rebased to 100: Lupin against the median of its 11 peers (local-currency closes).

Lupin financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹307B₹277B₹222B₹197B₹165B
Revenue growth—+24%+13%+19%—
Gross profit₹162B₹173B₹122B₹102B₹72.2B
EBITDA₹88.0B₹83.2B₹48.7B₹35.5B₹16.7B
Net income₹52.1B₹53.3B₹32.8B₹19.1B₹4.30B
Free cash flown/a₹51.4B₹12.2B₹24.8B₹2.03B
Capital expendituren/a₹20.5B₹16.8B₹9.29B₹15.0B
Total debt₹61.8B₹66.2B₹54.5B₹29.2B₹45.4B

Quarterly statements and history in the cockpit →

Lupin competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%+40%AUROPHARMA002001CIPLAABVX000423002603BHC002317000623RVMDLUPIN.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Lupin is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×50×AUROPHARMA002001CIPLA000423002603BHC002317LUPIN.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lupin is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%AUROPHARMA002001CIPLA000423002603BHC002317000623300146LUPIN.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lupin is the large dot.

Lupin competitors and peer comparison

Head to head with its named competitors (LUPIN.NS vs SUNPHARMA.NS vs CIPLA.NS vs DRREDDY.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%32.0×30.7%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%

How Lupin compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lupin against its 11 peers (data as of 18 Nov 2026)
MeasureLUPIN.NSPeer medianRank in peer set
1-month return+1.7%0.0%6th highest of 12
6-month return-13.8%+0.5%3rd lowest of 12
Distance from 52-week high-22.0%-23.0%5th highest of 12
Revenue growth (TTM)+24.2%+10.1%2nd highest of 10
Operating margin23.8%13.9%4th highest of 11
Forward P/E21.0×20.1×5th cheapest of 9
Growth the price implies (Req g, 7 yrs)8.8%4.8%4th most demanding of 10
Growth delivered (Del g)+13.0%+5.9%3rd highest of 10
Hurdle (Req g minus delivered)-4.2 pp+4.0 pp4th least demanding of 10
ROIC minus cost of capital+11.6 pp+2.5 pp4th highest of 10
EV / EBITDA10.1×13.4×2nd cheapest of 4
Net debt / EBITDA-0.1×-0.2×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lupin LUPIN.NSIndia$9.67B-14%+24%24%21.0×8.8%+13.0%
Aurobindo Pharma AUROPHARMA.NSIndia$11.0B+19%+14%15%22.3×21.1%+6.3%
Zhejiang NHU 002001.SZChina$11.8B-22%+11%33%9.7×-8.3%+16.7%
Cipla CIPLA.NSIndia$12.2B+1%-1%13%29.1×28.4%+8.1%
Abivax ABVX.PAFrance$7.36B-30%n/an/an/an/an/a
Dong-E-E-Jiao 000423.SZChina$4.99B+1%+8%29%17.8×-3.7%+14.5%
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Revolution Medicines RVMDUnited States$34.6B+6%n/a-853%n/an/an/a
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%

Questions

Who are Lupin's main competitors?
Named competitors: Sun Pharmaceutical (SUNPHARMA.NS), Cipla (CIPLA.NS), Dr. Reddy's Laboratories (DRREDDY.NS), Teva Pharmaceutical (TEVA), Viatris (VTRS). The cockpit's measured peer set (industry) also includes Aurobindo Pharma (AUROPHARMA.NS), Zhejiang NHU (002001.SZ), Cipla (CIPLA.NS), Abivax (ABVX.PA), Dong-E-E-Jiao (000423.SZ), Shijiazhuang Yiling Pharmaceutical (002603.SZ).
Is Lupin expensive compared with its peers?
On forward p/e it trades at 21.0× against a peer median of 20.1×, 5th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Lupin stock performed?
Over six months to 18 Nov 2026 the shares returned -13.8% against +0.5% for the median peer; over one year -3.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.